Marshall Wace
MAIA icon

Marshall Wace’s MAIA Biotechnology MAIA Stock Holding History

Marshall Wace’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-110,467
Closed -$170K – 3253
2025
Q3 		$170K Buy
110,467
+94,302
+583% +$154K ﹤0.01% 2591
2025
Q2 		$29.1K Buy
+16,165
New +$28.9K ﹤0.01% 2625

Other funds holding MAIA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $5.76B AUM 24.57% 1-Year Est. Return

Marshall Wace's MAIA Position: Q4 2025 in Review

Marshall Wace sold out of MAIA Biotechnology (MAIA) in Q4 2025, closing a stake of 110,467 shares — an estimated $170K sold.

Marshall Wace first reported a position in MAIA in Q2 2025 and held it in 2 quarters. The position peaked at $170K in Q3 2025. 26 funds tracked by Wall St. Rank hold MAIA as of Q4 2025.

  • Marshall Wace reported no remaining MAIA Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Marshall Wace sold 110,467 MAIA Biotechnology shares in Q4 2025, an estimated $170K.
  • Marshall Wace first reported a position in MAIA Biotechnology in Q2 2025 and held it in 2 quarters.
  • Marshall Wace's MAIA Biotechnology position peaked at $170K in Q3 2025.
  • 26 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.